Cargando…

The Future of Somatostatin Receptor Ligands in Acromegaly

Currently, the first-generation somatostatin receptor ligands (fg-SRLs), octreotide LAR and lanreotide autogel, are the mainstays of acromegaly treatment and achieve biochemical control in approximately 40% of patients and tumor shrinkage in over 60% of patients. Pasireotide, a second-generation SRL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gadelha, Monica R, Wildemberg, Luiz Eduardo, Kasuki, Leandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Mini-Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764337/ https://www.ncbi.nlm.nih.gov/pubmed/34618894 http://dx.doi.org/10.1210/clinem/dgab726

Ejemplares similares

MicroRNA in Acromegaly: Involvement in the Pathogenesis and in the Response to First-Generation Somatostatin Receptor Ligands
por: Henriques, Daniel G., et al.
Publicado: (2022)

gsp Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in Acromegaly
por: Wildemberg, Luiz Eduardo, et al.
Publicado: (2021)

miR-383-5p, miR-181a-5p, and miR-181b-5p as Predictors of Response to First-Generation Somatostatin Receptor Ligands in Acromegaly
por: Henriques, Daniel G., et al.
Publicado: (2023)

Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles
por: Coelho, Maria Caroline Alves, et al.
Publicado: (2019)

Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
por: Colao, Annamaria, et al.
Publicado: (2015)

Novel therapies for acromegaly
por: Maia, Bernardo, et al.
Publicado: (2020)

Combined treatment of somatostatin analogues with pegvisomant in acromegaly
por: Franck, S. E., et al.
Publicado: (2015)

The genetic background of acromegaly
por: Gadelha, Mônica R., et al.
Publicado: (2017)

Acromegaly and Colorectal Neoplasm: An Update
por: Kasuki, Leandro, et al.
Publicado: (2022)

Determinants of morbidities and mortality in acromegaly
por: Kasuki, Leandro, et al.
Publicado: (2019)

Novel Somatostatin Receptor Ligands Therapies for Acromegaly
por: Paragliola, Rosa Maria, et al.
Publicado: (2018)

Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly
por: Marques, Nelma Veronica, et al.
Publicado: (2023)

Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center: efficacy, safety and predictors of response
por: Kasuki, Leandro, et al.
Publicado: (2016)

Epithelial–Mesenchymal Transition in the Resistance to Somatostatin Receptor Ligands in Acromegaly
por: Gil, Joan, et al.
Publicado: (2021)

Molecular evidence and clinical importance of β‐arrestins expression in patients with acromegaly
por: Coelho, Maria Caroline Alves, et al.
Publicado: (2018)

Clinical Management of Acromegaly: Therapeutic Frontiers and New Perspectives for Somatostatin Receptor Ligands (SRLs)
por: Brunetti, Alessandro, et al.
Publicado: (2022)

Apoplexy in sporadic pituitary adenomas: a single referral center experience and AIP mutation analysis
por: Fialho, Christhiane, et al.
Publicado: (2021)

Successful Primary Medical Therapy with Somatostatin Receptor Ligand in Acromegaly with Thyroid Cancer
por: Dharan, Shalini Sree, et al.
Publicado: (2017)

OR01-01 Oral, Once-daily, Paltusotine (Non-peptide Selective Somatostatin Receptor Subtype 2 Agonist) Therapy In Patients With Acromegaly Is Associated With Long-term Biochemical And Symptom Control And Is Preferred Over Injectable Somatostatin-Receptor Ligands
por: Gadelha, Monica R, et al.
Publicado: (2023)

Pulmonary function testing and chest tomography in patients with acromegaly
por: Camilo, Gustavo Bittencourt, et al.
Publicado: (2013)

Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide
por: Samson, Susan L, et al.
Publicado: (2020)

Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience
por: Gadelha, Mônica, et al.
Publicado: (2023)

Clinical and functional variables can predict general fatigue in patients with acromegaly: an explanatory model approach
por: Michalski, André da Cunha, et al.
Publicado: (2019)

SAT-465 Somatostatin Receptor Ligand as Initial Therapy in a Patient with Pituitary Microadenoma and Acromegaly: Temporary Remission and Recurrence
por: Baby, Ann, et al.
Publicado: (2019)

Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly
por: Venegas‐Moreno, Eva, et al.
Publicado: (2017)

Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands
por: Fleseriu, Maria, et al.
Publicado: (2021)

Preoperative Medical Treatment for Patients With Acromegaly: Yes or No?
por: Albarel, Frederique, et al.
Publicado: (2022)

On the Functional Capacity and Quality of Life of Patients with Acromegaly: Are They Candidates for Rehabilitation Programs?
por: Guedes da Silva, Débora Pedroza, et al.
Publicado: (2013)

Improved Acromegaly Patient Satisfaction With Oral Octreotide Capsules Compared With Injectable Somatostatin Receptor Ligands in the MPOWERED Trial
por: Gordon, Murray B, et al.
Publicado: (2021)

Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review
por: Fleseriu, Maria
Publicado: (2010)

Biliary adverse events in acromegaly during somatostatin receptor ligands: predictors of onset and response to ursodeoxycholic acid treatment
por: Prencipe, N., et al.
Publicado: (2020)

Correction: ZAC1 and SSTR2 Are Downregulated in Non-Functioning Pituitary Adenomas but Not in somatotropinomas
por: Vieira Neto, Leonardo, et al.
Publicado: (2013)

ZAC1 and SSTR2 Are Downregulated in Non-Functioning Pituitary Adenomas but Not in somatotropinomas
por: Vieria Neto, Leonardo, et al.
Publicado: (2013)

Somatostatin Receptor Subtype Expression in Patients with Acromegaly and Complicated Clinical Course
por: Pichler, Robert, et al.
Publicado: (2021)

Identification of somatostatin receptor type 5 gene polymorphisms associated with acromegaly
por: Ciganoka, Darja, et al.
Publicado: (2011)

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
por: Gadelha, Mônica, et al.
Publicado: (2020)

Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective
por: Nista, Federica, et al.
Publicado: (2021)

Acromegaly Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis
por: Carmichael, John D., et al.
Publicado: (2014)

Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice
por: Geer, Eliza B., et al.
Publicado: (2020)

MON-LB50 Poor Response to Pre-Surgical Treatment With Somatostatin Receptor Ligands Is Associated With Diabetes Mellitus in Patients With Acromegaly
por: Frara, Stefano, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1hvp5c1dm54bkqeo9killvu4cq